A phase i study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer

Dustin A. Deming, Ludmila L. Cavalcante, Sam J. Lubner, Daniel L. Mulkerin, Noelle K. Loconte, Jens C. Eickhoff, Jill M. Kolesar, Suzanne Fioravanti, Tim F. Greten, Kathryn Compton, Austin G. Doyle, George Wilding, Austin Duffy, Glenn Liu

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Fingerprint

Dive into the research topics of 'A phase i study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science